894797-08-1Relevant articles and documents
SAR studies: Designing potent and selective LXR agonists
Szewczyk, Jason W.,Huang, Shaei,Chin, Jayne,Tian, Jenny,Mitnaul, Lyndon,Rosa, Raymond L.,Peterson, Larry,Sparrow, Carl P.,Adams, Alan D.
, p. 3055 - 3060 (2008/09/21)
Counterscreening compounds from a Merck PPAR program discovered lead 1, as a nanomolar LXR/PPAR dual agonist. SAR optimization developed a series of heterocyclic LXR agonists having excellent selectivity over all PPAR isoforms and possessing high LXR affi